Madopar Quick (Benserazide, Levodopa)

Levodopa crosses the blood‑brain barrier and is converted into dopamine, directly addressing the dopamine deficiency in Parkinson's disease. Benserazide inhibits the peripheral enzyme aromatic L‑amino acid decarboxylase, preventing levodopa from being metabolized outside the brain and thereby increasing its central availability.

The specific dose of Madopar Quick is individualized and determined by a qualified prescriber based on the patient's disease stage, response, and tolerability. Healthcare professionals adjust the regimen to achieve optimal symptom control while minimizing side effects.

Safety data for Madopar Quick in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To request Madopar Quick, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Madopar Quick combines levodopa with benserazide, offering higher central dopamine availability than levodopa alone. Compared with dopamine agonists, it provides more potent symptom relief but may have a higher risk of motor complications. Choice of therapy depends on disease stage, patient profile, and physician judgment.

Madopar Quick tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout their shelf life.

Madopar Quick is taken orally with water, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks include neuroleptic malignant syndrome, severe psychiatric disturbances such as hallucinations or severe depression, and dyskinesia that can affect daily activities. Patients should be monitored closely for any sudden changes in mental status, muscle rigidity, or uncontrolled movements.

Madopar Quick is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients, and in those taking non‑selective MAO inhibitors. Caution is also advised for individuals with severe cardiovascular disease, narrow‑angle glaucoma, or a history of malignant melanoma.